Cargando…

An overview of immune checkpoint inhibitors in breast cancer

Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miglietta, Federica, Cona, Maria Silvia, Dieci, Maria Vittoria, Guarneri, Valentina, La Verde, Nicla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Open Exploration 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400749/ https://www.ncbi.nlm.nih.gov/pubmed/36046385 http://dx.doi.org/10.37349/etat.2020.00029

Ejemplares similares

Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
por: Dieci, Maria Vittoria, et al.
Publicado: (2021)

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
por: Miglietta, Federica, et al.
Publicado: (2019)

Host-Related Factors in the Interplay among Inflammation, Immunity and Dormancy in Breast Cancer Recurrence and Prognosis: An Overview for Clinicians
por: Ruggieri, Lorenzo, et al.
Publicado: (2023)

The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies
por: Zarrilli, Giovanni, et al.
Publicado: (2020)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives
por: Carbognin, Luisa, et al.
Publicado: (2019)

Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer
por: Massa, Davide, et al.
Publicado: (2022)

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
por: Miglietta, F., et al.
Publicado: (2022)

Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review
por: Vernaci, Grazia Maria, et al.
Publicado: (2021)

Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?
por: Solinas, Cinzia, et al.
Publicado: (2021)

Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases
por: Bottosso, Michele, et al.
Publicado: (2023)

Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary
por: Giarratano, Tommaso, et al.
Publicado: (2018)

A comprehensive profiling of the immune microenvironment of breast cancer brain metastases
por: Griguolo, Gaia, et al.
Publicado: (2022)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Immune characterization of breast cancer metastases: prognostic implications
por: Dieci, Maria Vittoria, et al.
Publicado: (2018)

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials
por: Guarneri, V., et al.
Publicado: (2022)

Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment
por: Pirš, Boštjan, et al.
Publicado: (2022)

Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

Clinical development of mTOR inhibitors in breast cancer
por: Vicier, Cecile, et al.
Publicado: (2014)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
por: van Doorn, Diederick J., et al.
Publicado: (2020)

Erratum to ‘Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival’: [ESMO Open Volume 7, Issue 2, April 2022, 100409]
por: Miglietta, F., et al.
Publicado: (2022)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview
por: Li, Jingjing, et al.
Publicado: (2023)

An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors
por: Esposito, Roberta, et al.
Publicado: (2021)

Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2020)

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Vernaci, Grazia, et al.
Publicado: (2023)

HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
por: Miglietta, Federica, et al.
Publicado: (2022)

Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center
por: Tasca, Giulia, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
por: Borella, Fulvio, et al.
Publicado: (2020)

Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice
por: Giannini, Edoardo G., et al.
Publicado: (2019)

A proposal of a “ready to use” COVID-19 control strategy in an Oncology ward: Utopia or reality?
por: Dalu, Davide, et al.
Publicado: (2021)

Immune checkpoint inhibitors in penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2021)

Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases
por: Di Liso, Elisabetta, et al.
Publicado: (2020)

Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature
por: Thanopoulou, Eirini, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review
por: Nunes Filho, Paulo, et al.
Publicado: (2023)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
por: Dai, Xinlun, et al.
Publicado: (2020)

PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology
por: Miglietta, Federica, et al.
Publicado: (2022)

The emotional impact of the COVID-19 outbreak on cancer outpatients and their caregivers: results of a survey conducted in the midst of the Italian pandemic
por: Cona, Maria Silvia, et al.
Publicado: (2021)

Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease
por: Dieci, Maria Vittoria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0f8spv1si3bohc8gc21mb9u1mr